TTYP01 clinical trials
How each study uses TTYP01 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the TTYP01 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Shanghai Auzone Biological Technology Co., Ltd. (3)
Studies
Open first, then newest update. How each study uses TTYP01 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's DiseaseRecruitingPhase 2Shanghai Auzone Biological Technology Co., Ltd.NCT07252440Written as TTYP01 tables 60mg
- Evaluate the Efficacy and Safety of TTYP01 Tablets in Adolescents and Children With ASDRecruitingPhase 2Shanghai Auzone Biological Technology Co., Ltd.NCT06757504Written as TTYP01 Tablets (12mg or 18mg)
- Evaluate the Efficacy and Safety of TTYP01 Tablets in the Treatment of Acute Ischemic StrokeCompletedPhase 3Shanghai Auzone Biological Technology Co., Ltd.NCT06648304Written as TTYP01 tablets